Skip to main
INKT
INKT logo

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics Inc. demonstrates a positive outlook due to early evidence indicating improvements in pro-inflammatory markers, suggesting potential therapeutic responses in subsequent treatment cycles. The company is strategically engaging in investigator-sponsored trials that are externally funded, allowing MiNK to explore new indications without utilizing its own capital, which is favorable for financial management. Additionally, promising data around the efficacy of its iNKT cell therapies, particularly in delayed tumor progression and enhanced immune responses in cancer treatments, strengthens the company's position in the evolving biopharmaceutical landscape.

Bears say

The financial outlook for MiNK Therapeutics Inc. is marred by several fundamental risks, including potential safety issues and lower-than-expected efficacy from clinical programs, which could undermine investor confidence in the company’s pipeline. Additionally, there is a significant concern regarding the need for further financing, with estimates suggesting that the company may require around $55 million through 2038 to sustain operations, and a cash runway projected only until mid-2025. Compounding these issues is the looming threat of de-listing if share prices fall below $1, along with vulnerabilities related to regulatory decisions and intellectual property protections that could hinder the company’s commercialization efforts.

MiNK Therapeutics (INKT) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Buy based on their latest research and market trends.

According to 4 analysts, MiNK Therapeutics (INKT) has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.